Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06063278
Other study ID # IIBSP-BUL-2021-144
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date May 6, 2022
Est. completion date December 20, 2025

Study information

Verified date September 2023
Source Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Contact Cristina Carmona, PhD
Phone +34935537761
Email ccarmonaf@santpau.cat
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This a pseudo-randomized clinical trial that examines if a specific group therapy for BN is effective in improving its symptomatology, and what variables mediate such improvements. To do so a sample of 100 patients with BN will be pseudorandomized in a Group Therapy for BN or in a control waiting list group. Patients will be assessed at baseline, at the end of the group therapy and at 2 year follow up.


Description:

This is a controlled non randomized study that will compare a group of patients with BN that participate in the SBS group therapy with a group of BN patients who will be in wait list as a control condition. Patients for this single center trial will be recruited from the outpatient facility of the Hospital de la Santa Creu I Sant Pau (Barcelona, Spain). After assessed for eligibility participants will be given a set of self -report questionnaires. After the questionnaires are completed participants will be allocated to wait list condition or to the treatment arm. Time between assessment and starting the SBS group will be a month or least. Participants will be administered the same questionnaires the following month after finishing the treatment or after 3 to 4 months after the first assessment for the control condition.


Recruitment information / eligibility

Status Recruiting
Enrollment 100
Est. completion date December 20, 2025
Est. primary completion date May 6, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria: - Diagnostic of Bulimia Nervosa Exclusion Criteria: - Not understanding Spanish or Catalan Language

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
l Group Therapy for BN.
9 to 10 group sessions of 90 to 120min each

Locations

Country Name City State
Spain Hospital de la Santa Creu i Sant Pau Barcelona

Sponsors (1)

Lead Sponsor Collaborator
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau

Country where clinical trial is conducted

Spain, 

References & Publications (5)

- Andrade-González, N., & Fernández-Liria, A. (2016). Spanish adaptation of the working alliance inventory-short (WAI-S). Current Psychology, 35(1), 169-177.

Agh T, Kovacs G, Supina D, Pawaskar M, Herman BK, Voko Z, Sheehan DV. A systematic review of the health-related quality of life and economic burdens of anorexia nervosa, bulimia nervosa, and binge eating disorder. Eat Weight Disord. 2016 Sep;21(3):353-364. doi: 10.1007/s40519-016-0264-x. Epub 2016 Mar 4. — View Citation

Fairburn CG, Bailey-Straebler S, Basden S, Doll HA, Jones R, Murphy R, O'Connor ME, Cooper Z. A transdiagnostic comparison of enhanced cognitive behaviour therapy (CBT-E) and interpersonal psychotherapy in the treatment of eating disorders. Behav Res Ther. 2015 Jul;70:64-71. doi: 10.1016/j.brat.2015.04.010. Epub 2015 Apr 22. — View Citation

Hay P. A systematic review of evidence for psychological treatments in eating disorders: 2005-2012. Int J Eat Disord. 2013 Jul;46(5):462-9. doi: 10.1002/eat.22103. — View Citation

Polnay A, James VA, Hodges L, Murray GD, Munro C, Lawrie SM. Group therapy for people with bulimia nervosa: systematic review and meta-analysis. Psychol Med. 2014 Aug;44(11):2241-54. doi: 10.1017/S0033291713002791. Epub 2013 Nov 15. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Eating Attitudes Test, E-40. A self report questionarie that assesses eating disorder symptomatology. The range of scores is 0-78. Higher scores mean higher eating disorders sympthoms. 3 months
Primary Eating Disorder Inventory, EDI A self report questionarie that assesses eating disorder symptomatology. The range of scores is 0-192. Higher scores mean higher eating disorders sympthoms 3 months
Primary Bulimic Investigatory Test Edinburgh, BITE A self report questionarie that assesses bulimia nervosa symptomatology.The range of scores is 0-30. Higher scores mean higher bulimic sympthoms 3 months
Primary Body Shape Questionnaire, BSQ-34 A self report questionarie that assesses eating disorder symptomatology. The score is ranging between 34-204 points. Higher scores point to an increased level of concern on body shape. 3 months
Secondary Working alliance Inventory -short, WAIS. A self report questionarie that assesses bulimia nervosa symptomatology. Values range from 12 to 84. Hihger scores meaning higher therapeutic alliance. 3 months
Secondary Autism-Spectrum Quotient, AQ A self report questionarie that assesses autistic traits. The range of scores is 0 to 50. Higher scores mean higher autistic traits. 3 months
Secondary Quality of Life Enjoyment and Satisfaction Questionnaire, Q-LES-Q. A self report questionarie that assesses quality of life. The range of scores is 0-100. Higher scores mean higher quality of life. 3 months
Secondary Beck Depression Inventory, BDI-II A self report questionarie that assesses depressive symptoatology. The range of scores is 0-83. Higher scores mean higher depressive symptoms. 3 months
Secondary Rosenberg Self-Esteem Scale, RSE. A self report questionarie that assesses self steem. The scale ranges from 0-30. Higher scores mean higher self-esteem. The range scores is 0-60. 3 months
Secondary State -Trait Anxiety Inventory, STAI. A self report questionarie that assesses anxiety. Higher scores mean higher anxiety. 3 months
Secondary Difficulties in Emotion Regulation Scale (DERS). A self report questionarie that assesses emotion regulation difficulties. The scale ranges from 28-40. H igher scores indicate more difficulty in emotion regulation. 3 months
See also
  Status Clinical Trial Phase
Enrolling by invitation NCT04174703 - Preparing for Eating Disorders Treatment Through Compassionate Letter-Writing N/A
Terminated NCT04278755 - Binge Eating & Birth Control Phase 2
Withdrawn NCT02978742 - Evaluating and Implementing a Smartphone Application Treatment Program for Bulimia Nervosa and Binge Eating Disorder N/A
Withdrawn NCT00988481 - Topiramate Augmentation in Bulimia Nervosa Partial Responders Phase 4
Completed NCT00522769 - Cognitive Behavioral Therapy to Treat Bulimia Nervosa in Adolescents Phase 1/Phase 2
Completed NCT00184301 - A Comparison Study of Treatments Given to Patients With Concurrent Eating Disorder and Personality Disorder. N/A
Completed NCT00304187 - Effectiveness of Antibiotic Treatment for Reducing Binge Eating and Improving Digestive Function in Bulimia Nervosa Phase 2
Recruiting NCT04409457 - Self-Control in Bulimia Nervosa N/A
Recruiting NCT05509257 - Naltrexone Neuroimaging in Teens With Eating Disorders Early Phase 1
Recruiting NCT05937243 - Identifying Effective Technological-based Augmentations to Enhance Outcomes From Self-help Cognitive Behavior Therapy for Binge Eating N/A
Recruiting NCT05862389 - Study on the Mechanism of Eating Disorder
Recruiting NCT05728021 - Smartphone-based Aftercare for Inpatients With Bulimia Nervosa N/A
Completed NCT03781921 - The Neural Bases of Emotion Regulation in Bulimia Nervosa
Completed NCT02553824 - FDA Approved Medication to Reduce Binge Eating and/or Purging Phase 1
Recruiting NCT05575960 - Interpersonal Psychotherapy for Adolescents and Young Adults N/A
Terminated NCT04041024 - Decision-making and Risk-taking in Bulimia N/A
Completed NCT04265131 - Emotion Regulation in Eating Disorders: How Can Art Therapy Contribute to Treatment Outcome? N/A
Recruiting NCT02960152 - Periodontal Impact of Eating Disorders (the PERIOED Study) N/A
Completed NCT00916071 - Association Between Attention Deficit Hyperactivity Disorder and Bulimia Nervosa in Outpatients With Eating Disorders N/A
Terminated NCT00308776 - Cholecystokinin for Reducing Binge Eating in People With Bulimia Nervosa N/A